Suppression of the malignancy of mammary tumor in mice model by inactivated preparation of .

Breast cancer (BC) is a significant cause of global mortality in women. This study was aimed to evaluate the immune-activation of malignant BC via the administration of attenuated . For this purpose, an model was developed with BALB/c mice. Mice were injected with 2.00 × 10 4T1 cells with breast tumor cell line. Forty-two mice were equally divided into control as well as low dose (0.20 mg 100 µL) and high dose (0.50 mg 100 µL) groups of to investigate gene expression in the antitumor effects of . In one group, paclitaxel was administrated as a choice drug in BC treatment. Antitumor manners were characterized by cytotoxicity against tumor target cells, size of the tumor and the expression of some BC metastatic genes together with pathology. The MTT assay demonstrated that different concentrations of both low and a high dose of bacteria did present no cytotoxicity effect on 4T1 cells. According to our findings, significantly repressed tumor growth. downregulated the expression of collagen type I alpha 1 (COLIA1), cFos, alkaline phosphatase (ALP), claudin 3 (cldn3), and conversely, activated transcription factor 4 (ATF4) and Twist related protein-1 (Twist1). All these alternations induced a decrease in the migratory and invasive capabilities of BC. The result of pathology was indicative of tumor regression in the paclitaxel and HK- -recipient group. Thus, it seems most likely that might impinge upon cell growth and metastatic behavior of malignant cells exerting anti-tumor activity in BC.